Area of research
Public Health, Environmental and Occupational Health · Computational Theory and Mathematics
Research interest
Research focused on Malaria and Plasmodium falciparum, with related work in Druggability, Drug discovery, Plasmodium (life cycle). Notable publications include 'A novel multiple-stage antimalarial agent that inhibits protein synthesis', 'Targeting Plasmodium PI(4)K to eliminate malaria', and 'Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics'.
Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4
Drug resistance–associated mutations in Plasmodium UBP-1 disrupt its essential deubiquitinating activity
Optimization and Characterization of the Antimalarial Activity of <i>N</i>-Aryl Acetamides that are Susceptible to Mutations in ROM8 and CSC1
Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activity
Targeting Aurora Kinases as Essential Cell‐Cycle Regulators to Deliver Multi‐Stage Antimalarials Against <i>Plasmodium Falciparum</i>
2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of <i>Plasmodium falciparum</i> Phosphatidylinositol-4-kinase and Hemozoin Formation with <i>In Vivo</i> Efficacy
Systematic in vitro evolution in <i>Plasmodium falciparum</i> reveals key determinants of drug resistance
β-Carboline-3-carboxamide Antimalarials: Structure–Activity Relationship, ADME-Tox Studies, and Resistance Profiling
Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial Activity
Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy
Integrative Genetic Manipulation of <i>Plasmodium cynomolgi</i> Reveals Multidrug Resistance-1 Y976F Associated With Increased In Vitro Susceptibility to Mefloquine
The effect of cold water immersion on the recovery of physical performance revisited: A systematic review with meta-analysis
MalDA, Accelerating Malaria Drug Discovery
Prioritization of Molecular Targets for Antimalarial Drug Discovery
Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention
3D bioprinting and microscale organization of vascularized tissue constructs using collagen‐based bioink
Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity
Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway
Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue
UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes
A broad analysis of resistance development in the malaria parasite
CRISPR‐Cas9‐modified <i>pfmdr1</i> protects <i>Plasmodium falciparum</i> asexual blood stages and gametocytes against a class of piperazine‐containing compounds but potentiates artemisinin‐based combination therapy partner drugs
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Profiling the Essential Nature of Lipid Metabolism in Asexual Blood and Gametocyte Stages of Plasmodium falciparum
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of <i>Plasmodium</i>
KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission